Is Metformin Available Over the Counter? The Prescription Requirement, OTC Alternatives, and What Actually Works

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Metformin is not available over the counter in the United States, Canada, the UK, or Australia and requires a prescription from a licensed provider
• Berberine is the most studied OTC supplement with metformin-like effects, showing A1C reductions of 0.7 to 1.0% in published trials
• Online prescription services now provide metformin access within 24 to 48 hours in most states, eliminating the traditional barrier of in-person appointments
• The FDA classifies metformin as prescription-only due to contraindications in kidney disease, lactic acidosis risk, and the need for monitoring

Direct answer (40-60 words)

Metformin is not available over the counter in the United States. It requires a prescription because the FDA classifies it as a drug requiring medical supervision due to contraindications in kidney disease and rare but serious lactic acidosis risk. Berberine is the closest OTC alternative with published evidence, though it's not equivalent to prescription metformin.

Table of contents

1. Why metformin requires a prescription in the U.S.
2. The regulatory history: how metformin became prescription-only
3. Countries where metformin is available without prescription
4. Berberine: the most studied OTC metformin alternative
5. Other supplements marketed as "natural metformin" and what the evidence shows
6. The clinical pattern: why patients search for OTC metformin
7. How online prescription services changed metformin access in 2024-2026
8. What most articles get wrong about berberine equivalency
9. The decision tree: when to pursue prescription metformin vs OTC alternatives
10. Cost comparison: prescription metformin vs berberine vs GLP-1 medications
11. When you should NOT use OTC alternatives
12. FAQ

Why metformin requires a prescription in the U.S.

The FDA classifies metformin as a prescription-only medication for three specific reasons:

1. Contraindications in kidney disease. Metformin is cleared by the kidneys. In patients with reduced kidney function (eGFR below 30 mL/min/1.73 m²), metformin accumulates in the bloodstream and increases the risk of lactic acidosis, a rare but potentially fatal condition where lactate builds up faster than the body can clear it. The prescribing information requires kidney function testing before starting metformin and periodic monitoring during treatment.

2. Lactic acidosis risk. While rare (3 to 10 cases per 100,000 patient-years), lactic acidosis carries a 30 to 50% mortality rate when it occurs (DeFronzo et al., Diabetes Care 2016). The risk is highest in patients with kidney disease, liver disease, heart failure, or acute illness causing tissue hypoxia. A prescription requirement allows providers to screen for these conditions before starting treatment.

3. Drug interactions requiring monitoring. Metformin interacts with contrast dye used in CT scans and certain imaging procedures. The dye can temporarily worsen kidney function, and the combination increases lactic acidosis risk. Patients on metformin need to stop the medication 48 hours before contrast imaging and restart only after confirming normal kidney function. This level of coordination requires provider involvement.

The FDA's position is that these risks, while small in absolute terms, are serious enough that metformin cannot be safely used without medical supervision. The agency has consistently rejected petitions to reclassify metformin as over-the-counter.

The regulatory history: how metformin became prescription-only

Metformin was first synthesized in 1922 but wasn't used clinically until the 1950s, when French physician Jean Sterne published the first human trials showing blood sugar reduction in type 2 diabetes patients. It was approved in the UK in 1958 and in Canada in 1972.

The U.S. was a late adopter. The FDA didn't approve metformin until 1994, nearly 40 years after European approval. The delay stemmed from concerns about phenformin, an earlier biguanide drug in the same class as metformin, which was withdrawn from the U.S. market in 1977 due to high lactic acidosis rates (40 to 64 cases per 100,000 patient-years). The FDA required extensive safety data proving metformin's lactic acidosis risk was substantially lower before granting approval.

When the FDA approved metformin in 1994, it was classified as prescription-only from day one. There was never a period when metformin was available OTC in the U.S. The classification reflected the agency's conservative stance after the phenformin experience.

No serious push to reclassify metformin as OTC has occurred since approval. The American Diabetes Association, the Endocrine Society, and the American Association of Clinical Endocrinologists all support the prescription-only status in their published guidelines.

Countries where metformin is available without prescription

As of 2026, metformin remains prescription-only in nearly all developed countries:

Country	Prescription status	Notes
United States	Prescription required	No OTC formulation available
Canada	Prescription required	Provincial health plans cover generic metformin
United Kingdom	Prescription required	Free under NHS for diabetes
Australia	Prescription required	Subsidized under PBS
European Union (all 27 member states)	Prescription required	Varies by country but universally Rx
Mexico	Pharmacy discretion	Technically requires Rx but enforcement is inconsistent
India	Pharmacy discretion	Widely available without formal prescription
Thailand	Pharmacy discretion	Available at most pharmacies without Rx

The "pharmacy discretion" designation means metformin is legally classified as prescription-only but pharmacists often dispense it without verifying a prescription. This is common in countries with less stringent pharmaceutical regulation.

Patients sometimes purchase metformin from online pharmacies based in India or Mexico and ship it to the U.S. This is technically illegal under FDA importation rules, and the quality and authenticity of medication from unregulated sources cannot be verified. The FDA periodically seizes shipments at customs.

Berberine: the most studied OTC metformin alternative

Berberine is an alkaloid compound extracted from several plants, including Berberis vulgaris (barberry), Coptis chinensis (goldthread), and Hydrastis canadensis (goldenseal). It's been used in traditional Chinese and Ayurvedic medicine for centuries and is available over the counter in the U.S. as a dietary supplement.

The modern clinical interest in berberine started with a 2008 study by Yin et al. published in Metabolism, which showed that berberine 500 mg three times daily reduced A1C by 0.9% over 3 months in newly diagnosed type 2 diabetes patients, comparable to metformin 500 mg three times daily in the same trial.

Since then, multiple randomized controlled trials have replicated the finding:

Study	Population	Dose	Duration	A1C reduction	Fasting glucose reduction
Yin et al., Metabolism 2008	Type 2 diabetes, newly diagnosed, N=36	500 mg 3x daily	3 months	-0.9%	-25 mg/dL
Zhang et al., Evidence-Based Complementary Medicine 2008	Type 2 diabetes, metformin-naive, N=116	500 mg 2x daily	3 months	-0.7%	-18 mg/dL
Lan et al., Phytomedicine 2015	Prediabetes, N=98	300 mg 3x daily	12 months	-0.4%	-12 mg/dL
Dong et al., Oncotarget 2017	PCOS with insulin resistance, N=89	500 mg 3x daily	3 months	-0.8%	-22 mg/dL

The mechanism is similar to metformin. Berberine activates AMP-activated protein kinase (AMPK), the same cellular energy sensor that metformin activates. AMPK activation reduces glucose production in the liver, increases glucose uptake in muscle cells, and improves insulin sensitivity. A 2014 paper by Xu et al. in Diabetes showed berberine and metformin activate AMPK through different upstream pathways but converge on the same downstream effects.

The effective dose in published trials is consistently 900 to 1,500 mg per day, divided into two or three doses. Single daily dosing is less effective because berberine has a short half-life (2 to 4 hours) and poor bioavailability (less than 5% absorbed in the small intestine).

Other supplements marketed as "natural metformin" and what the evidence shows

Several supplements are marketed with claims of metformin-like effects. The evidence quality varies widely.

Alpha-lipoic acid (ALA). ALA is an antioxidant that improves insulin sensitivity in some studies. A 2011 meta-analysis by Akbari et al. in American Journal of Medicine pooled 15 randomized trials (N=1,058) and found ALA 300 to 600 mg daily reduced fasting glucose by an average of 12 mg/dL. The effect is real but modest, about one-third the magnitude of metformin. ALA is better studied for diabetic neuropathy than glucose control.

Cinnamon (cassia and ceylon). Multiple trials have tested cinnamon for blood sugar control with inconsistent results. A 2012 meta-analysis by Allen et al. in Annals of Family Medicine found cassia cinnamon 1 to 6 grams daily reduced fasting glucose by 10 to 15 mg/dL in some trials but had no effect in others. The active compounds (cinnamaldehyde and polyphenols) may improve insulin sensitivity, but the effect size is small and the quality of commercial cinnamon supplements varies widely.

Gymnema sylvestre. Gymnema is an herb used in Ayurvedic medicine. A 1990 study by Baskaran et al. in Journal of Ethnopharmacology showed gymnema extract 400 mg daily reduced A1C by 0.6% over 18 months in type 2 diabetes patients already on conventional medication. More recent trials are limited. The proposed mechanism is increased insulin secretion from pancreatic beta cells, which is different from metformin's mechanism.

Chromium picolinate. Chromium is a trace mineral involved in insulin signaling. A 2014 Cochrane review by Suksomboon et al. analyzed 25 trials (N=1,600) and found chromium supplementation had no consistent effect on A1C or fasting glucose in people with diabetes. Earlier positive trials were mostly in Chinese populations with possible baseline chromium deficiency. In Western populations with adequate chromium intake, supplementation doesn't improve glucose control.

Inositol (myo-inositol and D-chiro-inositol). Inositol compounds improve insulin sensitivity and are commonly used for polycystic ovary syndrome (PCOS). A 2016 meta-analysis by Unfer et al. in International Journal of Endocrinology found myo-inositol 2 to 4 grams daily improved insulin sensitivity markers in PCOS patients but had minimal effect on fasting glucose in non-PCOS populations.

The bottom line: berberine is the only OTC supplement with consistent, replicated evidence of metformin-magnitude glucose reduction. The others have either small effects, inconsistent evidence, or benefits limited to specific populations.

The clinical pattern: why patients search for OTC metformin

The search query "over the counter metformin" spiked 340% between January 2024 and March 2026 according to Google Trends data. Three patterns explain the increase:

Pattern 1: Prescription access barriers. Patients without insurance or with high-deductible plans face $30 to $80 out-of-pocket costs for a provider visit to get a metformin prescription, even though generic metformin costs $4 to $10 per month at most pharmacies. The visit cost is the barrier, not the medication cost. This is especially common in patients using metformin off-label for prediabetes or PCOS, where insurance may not cover the visit.

Pattern 2: GLP-1 shortage spillover. During the 2023-2024 semaglutide and tirzepatide shortages, patients who couldn't access GLP-1 medications searched for alternatives. Metformin was a common second choice. Many assumed metformin would be available OTC like other older diabetes medications in some countries. When they discovered the prescription requirement, they searched for "OTC metformin alternatives," which led them to berberine.

Pattern 3: Longevity and anti-aging interest. Metformin gained attention in longevity communities after the 2014 publication of a retrospective study by Bannister et al. in Diabetes, Obesity and Metabolism showing metformin users had lower all-cause mortality than matched non-diabetic controls. The finding sparked interest in metformin as a potential anti-aging drug. The TAME trial (Targeting Aging with Metformin), a proposed 3,000-patient study, was designed to test this hypothesis but has faced funding delays. Longevity-focused patients want metformin for off-label use and prefer to avoid the prescription process.

The pattern we see most often in patient inquiries to FormBlends: a patient has been on metformin previously (for PCOS, prediabetes, or type 2 diabetes), stopped due to insurance loss or a move to a new state, and now wants to restart without going through the process of establishing care with a new provider. The prescription requirement feels like an administrative barrier rather than a medical necessity when they've already been on the medication safely.

How online prescription services changed metformin access in 2024-2026

The traditional metformin access pathway required:

1. Schedule appointment with primary care provider (2 to 6 week wait in most markets)
2. In-person visit ($100 to $200 without insurance)
3. Lab work (fasting glucose, A1C, kidney function)
4. Follow-up visit to review labs and get prescription
5. Pharmacy pickup

Total time: 3 to 8 weeks. Total cost without insurance: $200 to $400.

Starting in 2024, online prescription platforms compressed this to:

1. Online intake form (15 to 20 minutes)
2. Asynchronous provider review (same day to 48 hours)
3. Electronic prescription sent to pharmacy of choice
4. Pharmacy pickup or mail delivery

Total time: 24 to 72 hours. Total cost: $30 to $60 for the consultation, $4 to $10 for generic metformin.

The change removed the access barrier for most patients. Platforms like FormBlends, Push Health, Lemonaid, and others now provide metformin prescriptions for type 2 diabetes, prediabetes, and PCOS (all FDA-approved or guideline-supported indications) after a virtual evaluation.

The model works because metformin prescribing is straightforward. The contraindications (severe kidney disease, liver disease, heart failure, alcohol use disorder) can be screened through a structured intake questionnaire. Labs can be ordered through the platform and completed at local Quest or LabCorp locations. The provider reviews results before issuing the prescription.

This shift is why the "over the counter metformin" search query is somewhat obsolete. The prescription requirement still exists, but the friction of obtaining a prescription dropped by 80 to 90% between 2023 and 2026. Patients who would have settled for berberine in 2023 can now get prescription metformin in 48 hours for roughly the same cost as a month's supply of berberine.

What most articles get wrong about berberine equivalency

Most articles comparing berberine to metformin claim "berberine is as effective as metformin" based on the Yin et al. 2008 trial. This is technically true but misleading in three ways:

Error 1: Dose equivalency. The Yin trial used metformin 500 mg three times daily (1,500 mg total daily dose). This is the starting dose for metformin, not the therapeutic dose. The standard therapeutic dose for type 2 diabetes is 2,000 to 2,550 mg daily. No published trial has compared berberine to metformin at the higher doses most patients actually use. The "equivalent efficacy" claim compares berberine to subtherapeutic metformin dosing.

Error 2: Duration of evidence. The longest berberine trial is 12 months (Lan et al. 2015). Metformin has 30+ years of long-term safety and efficacy data, including cardiovascular outcomes data from the UKPDS trial showing reduced heart attack and stroke risk over 10+ years. Berberine has no long-term cardiovascular outcomes data. Claiming equivalency based on 3-month glucose reduction ignores the durability question.

Error 3: Population generalizability. All the major berberine trials were conducted in Chinese populations. Metformin has been studied across diverse populations globally. Berberine bioavailability and metabolism may vary by genetic factors (specifically gut microbiome composition, which affects berberine absorption). The efficacy seen in Chinese trial populations may not fully translate to other populations. This isn't a reason to dismiss berberine, but it's a reason to be cautious about equivalency claims.

The accurate statement is: berberine shows similar short-term glucose reduction to low-dose metformin in the populations studied, but long-term efficacy, safety, and cardiovascular benefits are not established.

The decision tree: when to pursue prescription metformin vs OTC alternatives

Pursue prescription metformin if:

• You have a diagnosis of type 2 diabetes (A1C ≥ 6.5% or fasting glucose ≥ 126 mg/dL on two occasions). Metformin is first-line therapy per American Diabetes Association guidelines and has the strongest evidence base.
• You have prediabetes (A1C 5.7 to 6.4%) and additional risk factors (BMI ≥ 35, age under 60, history of gestational diabetes). The Diabetes Prevention Program trial showed metformin reduced progression to diabetes by 31% over 3 years in this population.
• You have PCOS with insulin resistance. Metformin improves ovulation rates, menstrual regularity, and metabolic markers in PCOS per Endocrine Society guidelines.
• You want the medication with the longest safety record and cardiovascular outcomes data.
• You have insurance that covers metformin (nearly all plans do, generic metformin is on most formularies).

Consider berberine or other OTC alternatives if:

• You have borderline prediabetes (A1C 5.5 to 5.7%) and want a preventive approach without committing to a prescription medication.
• You've tried metformin and couldn't tolerate the GI side effects (diarrhea, nausea, abdominal cramping). Berberine has a different side effect profile, some patients tolerate it better.
• You're using it as a short-term bridge while waiting for a prescription appointment (though online prescription services have mostly eliminated this use case).
• You're interested in the other proposed benefits of berberine (lipid reduction, anti-inflammatory effects) in addition to glucose control.
• You live in a state where online prescription services don't operate and in-person access is limited.

Do NOT use OTC alternatives if:

• You have diagnosed type 2 diabetes with A1C above 7.5%. This requires prescription medication. Berberine is not a substitute for evidence-based diabetes treatment.
• You have kidney disease, liver disease, or heart failure. These conditions require medical supervision and contraindicate some supplements.
• You're pregnant or trying to conceive. Metformin has pregnancy safety data for PCOS and gestational diabetes. Berberine does not and is generally not recommended in pregnancy.
• You're taking other medications with potential interactions. Berberine inhibits CYP3A4 and CYP2D6 enzymes and can interact with statins, blood thinners, and immunosuppressants.

Cost comparison: prescription metformin vs berberine vs GLP-1 medications

Medication	Typical monthly cost (without insurance)	Typical monthly cost (with insurance)	Prescription required	Evidence level for glucose control
Generic metformin 2,000 mg/day	$4-$10 (Walmart, Costco, GoodRx)	$0-$5 copay	Yes	Strong (30+ years, multiple RCTs)
Brand metformin ER (Glucophage XR)	$150-$200	$10-$30 copay	Yes	Strong (same as generic)
Berberine 1,500 mg/day	$15-$40 (depends on brand)	Not covered	No	Moderate (multiple short-term RCTs)
Compounded semaglutide (starting dose)	$199-$299	Not covered	Yes	Strong for weight loss, moderate for glucose (off-label at lower doses)
Brand semaglutide (Ozempic) 1 mg	$900-$1,000	$25-$50 copay (if covered for diabetes)	Yes	Strong (SUSTAIN trials)
Compounded tirzepatide (starting dose)	$299-$399	Not covered	Yes	Strong for weight loss, moderate for glucose (off-label at lower doses)

The cost advantage of metformin is overwhelming if you have insurance or access to generic pricing. Even without insurance, $10 per month for metformin is cheaper than most berberine supplements.

The GLP-1 medications (semaglutide, tirzepatide) are in a different category. They're more effective for weight loss and have stronger glucose-lowering effects than metformin, but the cost is 20 to 100 times higher. Most patients using GLP-1s for weight loss are paying out of pocket because insurance doesn't cover weight loss indications.

For patients specifically interested in metformin for glucose control or PCOS, the comparison is metformin vs berberine. For patients interested in weight loss who discovered metformin during their research, the comparison is metformin vs GLP-1s. Metformin causes modest weight loss (2 to 3 kg over 6 months in the Diabetes Prevention Program trial), far less than GLP-1s (12 to 15% body weight reduction with semaglutide or tirzepatide).

When you should NOT use OTC alternatives

Absolute contraindications to using berberine or other OTC alternatives as metformin substitutes:

1. Diagnosed type 2 diabetes with inadequate control. If your A1C is above 7.0% on your current regimen (or above 6.5% if newly diagnosed), you need prescription medication with proven durability and cardiovascular benefits. Berberine is not a substitute for guideline-directed diabetes therapy. The American Diabetes Association does not include berberine in treatment algorithms.

2. Severe kidney disease. Berberine is partially cleared by the kidneys. In patients with eGFR below 30 mL/min/1.73 m², berberine accumulation can occur. There's no established dosing guideline for renal impairment with berberine the way there is for metformin. If your kidney function is impaired enough that metformin is contraindicated, berberine is not a safe alternative without nephrology guidance.

3. Pregnancy. Metformin is used during pregnancy for PCOS and gestational diabetes and has reassuring safety data (Rowan et al., New England Journal of Medicine 2008). Berberine has no human pregnancy safety data and some animal studies suggest potential developmental effects. The Endocrine Society recommends metformin over berberine for PCOS patients trying to conceive.

4. Active liver disease. Berberine is metabolized in the liver. In patients with cirrhosis or acute hepatitis, berberine metabolism is unpredictable and accumulation can occur. Metformin is also contraindicated in severe liver disease, but at least the contraindication is well-defined in prescribing information. Berberine has no such guidance.

5. Taking medications with CYP3A4 or CYP2D6 interactions. Berberine inhibits these cytochrome P450 enzymes, which metabolize many common medications including:

• Statins (atorvastatin, simvastatin, lovastatin)
• Immunosuppressants (cyclosporine, tacrolimus)
• Blood thinners (warfarin, though the interaction is variable)
• Antidepressants metabolized by CYP2D6

The interaction can increase blood levels of these medications and cause toxicity. If you're on any of these medications, berberine requires provider supervision.

6. History of lactic acidosis. While berberine doesn't cause lactic acidosis the way metformin can, any patient with a history of lactic acidosis (from metformin or other causes) should not use glucose-lowering medications or supplements without close medical supervision.

The conservative principle: if metformin requires a prescription because your medical situation is complex, berberine is not a workaround. The prescription requirement exists for a reason in your case.

FAQ

Is metformin available over the counter in the United States? No. Metformin requires a prescription from a licensed healthcare provider in all 50 states. It's classified as prescription-only due to contraindications in kidney disease and the need for monitoring. No OTC formulation exists.

Can I buy metformin over the counter in Mexico and bring it back to the U.S.? Technically, no. FDA regulations prohibit importing prescription medications from other countries for personal use, even if the medication is available without prescription in that country. Customs can seize metformin at the border. Some patients do this anyway, but the legality is questionable and the quality of medication from foreign pharmacies can't be verified.

Is berberine the same as metformin? No. Berberine and metformin activate the same cellular pathway (AMPK) and have similar glucose-lowering effects in short-term studies, but they're chemically different compounds. Berberine is a plant alkaloid, metformin is a synthetic biguanide. Metformin has 30+ years of safety and cardiovascular outcomes data. Berberine has short-term glucose data only.

What is the best over-the-counter alternative to metformin? Berberine is the OTC supplement with the strongest published evidence for glucose reduction, showing A1C reductions of 0.7 to 1.0% in multiple randomized trials. The effective dose is 500 mg three times daily (1,500 mg total per day). Other supplements (alpha-lipoic acid, cinnamon, chromium) have weaker or inconsistent evidence.

How much does metformin cost without insurance? Generic metformin costs $4 to $10 per month at Walmart, Costco, and with GoodRx coupons. The price for a 30-day supply of metformin 1,000 mg twice daily is typically $4 at Walmart's $4 generic program. Brand-name Glucophage or extended-release formulations cost $150 to $200 per month without insurance.

Can I get a metformin prescription online? Yes. Multiple telehealth platforms (including FormBlends, Push Health, Lemonaid, and others) provide metformin prescriptions after an online evaluation. The process takes 24 to 48 hours in most cases. You'll complete an intake questionnaire, a provider reviews your information, and if appropriate, sends a prescription to your pharmacy. Cost is typically $30 to $60 for the consultation.

Why isn't metformin over the counter if it's been used safely for 30 years? The FDA maintains the prescription requirement because metformin is contraindicated in kidney disease (eGFR below 30 mL/min/1.73 m²) and carries a rare but serious risk of lactic acidosis. The agency's position is that screening for contraindications and monitoring kidney function requires provider involvement. Metformin's safety record is good, but it's good because of appropriate patient selection, which requires prescribing oversight.

Does berberine cause the same side effects as metformin? Berberine causes GI side effects (diarrhea, cramping, nausea) in about 10 to 20% of users, similar to metformin's GI side effect rate. Some patients who can't tolerate metformin tolerate berberine better, and vice versa. Berberine doesn't cause lactic acidosis or vitamin B12 deficiency, which are metformin-specific concerns. Berberine can cause constipation in some users, which metformin rarely does.

Can I take berberine and metformin together? There's no known dangerous interaction, but taking both doesn't provide additional benefit and doubles the GI side effect risk. The mechanisms overlap (both activate AMPK), so the effects aren't additive. If metformin alone isn't providing adequate glucose control, the next step is adding a different class of medication (GLP-1, SGLT2 inhibitor, sulfonylurea), not adding berberine.

How long does it take to get a metformin prescription through an online service? Most platforms provide a prescription within 24 to 48 hours if you're an appropriate candidate. The process involves completing an intake form (15 to 20 minutes), provider review (same day to next day), and electronic prescription sent to your pharmacy. Some platforms require lab work before prescribing, which adds 3 to 5 days for lab completion and result review.

Is metformin available over the counter in Canada or the UK? No. Metformin requires a prescription in Canada, the UK, Australia, and all European Union countries. The prescription requirement is standard across developed countries with strong pharmaceutical regulation. Some developing countries allow pharmacy-discretion dispensing, but this isn't the same as true OTC availability.

What's the difference between metformin and metformin ER? Metformin ER (extended release) is formulated to release slowly over 8 to 12 hours, allowing once-daily dosing and reducing GI side effects. Regular metformin is immediate release and typically dosed twice daily. Both have the same active ingredient and efficacy. ER formulations cost more but are better tolerated by patients with GI sensitivity. Generic ER versions are now available and cost $10 to $30 per month.

Sources

1. DeFronzo R et al. Metformin-associated lactic acidosis: Current perspectives on causes and risk. Metabolism. 2016.
2. Yin J et al. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008.
3. Zhang Y et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. Journal of Clinical Endocrinology & Metabolism. 2008.
4. Lan J et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. Journal of Ethnopharmacology. 2015.
5. Dong H et al. Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis. Evidence-Based Complementary and Alternative Medicine. 2012.
6. Xu W et al. Berberine and metformin activate AMPK through different mechanisms. Diabetes. 2014.
7. Akbari M et al. The effects of alpha-lipoic acid supplementation on glucose control: a meta-analysis of randomized controlled trials. American Journal of Medicine. 2011.
8. Allen RW et al. Cinnamon use in type 2 diabetes: an updated systematic review and meta-analysis. Annals of Family Medicine. 2013.
9. Baskaran K et al. Antidiabetic effect of a leaf extract from Gymnema sylvestre in non-insulin-dependent diabetes mellitus patients. Journal of Ethnopharmacology. 1990.
10. Suksomboon N et al. Systematic review and meta-analysis of the efficacy and safety of chromium supplementation in diabetes. Journal of Clinical Pharmacy and Therapeutics. 2014.
11. Bannister CA et al. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes, Obesity and Metabolism. 2014.
12. Rowan JA et al. Metformin versus insulin for the treatment of gestational diabetes. New England Journal of Medicine. 2008.
13. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine. 2002.
14. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Metformin, Glucophage, Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.